-
Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests. -
Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care. -
We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company. -
Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.
Heparin Binding Protein
Sepsis is the body's systemic inflammatory response to infection and can progress to severe sepsis, septic shock and ultimately multiple organ failure.
Early diagnosis and appropriate treatment of severe sepsis is vital to improve the patient's chance of survival.
Heparin Binding Protein is a new marker which has been shown to be useful in identifying patients on admission to the Emergency Department who are at risk of developing severe sepsis with circulatory failure.
Click the image to download our brochure
Published data suggests that Heparin Binding Protein exhibits superior performance over existing biomarkers for the assessment of severe sepsis.
Axis-Shield will launch the first assay for measuring Heparin Binding Protein in December 2012.
For more information on this important new marker please visit www.heparinbindingprotein.com
Axis-Shield at a Glance
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
Focus on Afinion
Axis-Shield's award winning point-of-care test system is designed for maximum simplicity coupled with laboratory accuracy and reliability for a number of key markers important for improved patient management.
